Last reviewed · How we verify
Placebo + usual care
Placebo plus usual care serves as a control arm in clinical trials, providing no active pharmacological intervention beyond standard medical management.
At a glance
| Generic name | Placebo + usual care |
|---|---|
| Sponsor | The University of Hong Kong |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
This is a control comparator used in randomized controlled trials rather than an active drug. Placebo provides no mechanistic action itself; it is administered alongside usual care (standard treatment) to establish a baseline against which the efficacy and safety of an investigational drug can be measured. The combination allows researchers to isolate the effect of the experimental intervention from natural disease progression and standard care effects.
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer (PHASE3)
- A Graphene Far-infrared Intervention Study of Cognitive Status in Older Adults (NA)
- A Clinical Study of Dihydroergotine Mesylate Extended-release Tablets for the Treatment of Drooling in Parkinson's Disease. (PHASE4)
- Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus (PHASE2)
- Mobile Shared Decision-Making Program for ICU Caregivers (NA)
- Effects of Vibration-Assisted Physical Activity in Type-2 Diabetes (NA)
- RECOVER-AUTONOMIC Platform Protocol (PHASE2)
- RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo + usual care CI brief — competitive landscape report
- Placebo + usual care updates RSS · CI watch RSS
- The University of Hong Kong portfolio CI